Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT13722

Small molecule · developed by Prelude Therapeutics

Phase 1 Most advanced trial
PRLD Developer
1 Registered trials

What is PRT13722?

PRT13722 is an investigational oral drug given once daily. It is studied in hormone-receptor-positive, HER2-negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07905001 Phase 1 Breast Cancer Recruiting PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerHER2-negative Breast CancerHormone-receptor-positive Breast CancerHR-positive Breast CancerHR+/HER2- Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer

More from Prelude Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT13722

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.